Eli Lilly, a global health care provider, agreed to acquire Protomer Technologies, a private biotech company, for c. $1bn. "Lilly has long strived to make life better for people living with diabetes and we have a continued determination to provide real solutions, including innovation in insulin therapy. Glucose-sensing insulin is the next frontier and has the potential to revolutionize the treatment and quality of life of people with diabetes by dramatically improving both therapeutic efficacy and safety of insulin therapy," Ruth Gimeno, Vice President, Lilly Diabetes Research and Clinical Investigation.